VEGFA and breast cancer: Furthermore, in various cancer types such as colorectal, ovarian or breast cancers, anti-angiogenic treatment (anti-VEGF antibody) and anti-PD1 antibody therapies are approved individually, accordingly it is expected that such combinations will also be a part of clinical management of patients soon.